Novartis AG, of Basel, Switzerland, said immunotherapy, CTL019, that was the subject of a study partly funded by the Leukemia & Lymphoma Society (LLS) over the past 22 years and published in the New England Journal of Medicine, showed that 90 percent of children and adults with acute lymphoblastic leukemia (ALL) achieved complete remission after receiving the investigational personalized cellular therapy.